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Mutations in RAB27A, LYST, and AP3B1 give rise to FHL
associated with oculocutaneous albinism, and patients with FHL
are usually only screened for mutations in these genes when
albinism is observed. A number of patients with FHL and normal
pigmentation remain without a genetic diagnosis.
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1310Results: We identify patients with Griscelli syndrome type 2
with biallelic mutations in RAB27A in the absence of albinism.
All 6 patients carried mutations at amino acids R141, Y159,
or S163 of Rab27a that disrupt the interaction of Rab27a with
Munc13-4, without impairing the interaction between
melanophilin and Rab27a.
Conclusion: These studies highlight the need for RAB27A
sequencing in patients with FHL with normal pigmentation and
identify a critical binding site for Munc13-4 on Rab27a,
revealing the molecular basis of this interaction. (J Allergy Clin
Immunol 2015;135:1310-8.)
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Familial hemophagocytic lymphohistiocytosis (FHL; Online
Mendelian Inheritance in Man [OMIM] 267700) is a genetically
heterogeneous disorder characterized by a hyperinflammatory
syndrome with fever, hepatosplenomegaly, cytopenia, and
sometimes central nervous system involvement. Bone marrow
aspiration is usually performed early during the diagnostic
work-up, enabling the identification of hemophagocytosis by
activated macrophages. In most cases the natural course of
FHL is rapidly fatal within a few weeks unless appropriate
treatment, including corticosteroids, cyclosporine, etoposide, and
anti-thymocyte globulin, results in transient disease control.1
To date, only patients undergoing hematopoietic stem cell
transplantation have been cured.1-6 FHL is associated with
hyperactivation of the immune system, which is thought to result
from the failure of activated cytotoxic T lymphocytes (CTLs)
and natural killer (NK) cells to clear virally infected cells and
terminate the immune response. The failure to clear virally
infected cells is thought to lead to the activation and uncontrolled
expansion of polyclonal CD81 T cells and give rise tomacrophage
activation, with infiltration of tissues and organs, excessive release
of inflammatory cytokines, and resultant tissue damage.7,8
Diagnosing FHL has remained a challenge for many years.
Initially, the diagnostic criteria established by the Histiocyte
Society were key and included a collection of both clinical and
biochemical features. These diagnostic criteria have been updated
to introduce hyperferritinemia, defective NK cell activity, and
soluble CD25 levels.9 A better understanding of the pathogenic
mechanisms of FHL has provided a rationale for developing
novel, sensitive, and specific diagnostic tools based on flow
cytometric analysis of peripheral blood cells, including
defective expression of intracellular perforin and defective
degranulation.10,11 However, the gold standard for diagnosing
FHL remains mutational analysis of FHL-related genes. This is
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hematopoietic stem cell transplantation12,13 and whether prenatal
diagnosis is appropriate within families.
Since 1999, several genes have been associated with FHL:
PRF1 (OMIM *170280), UNC13-D (OMIM *608897), STX11
(OMIM *605014), and STXBP2 (OMIM *601717), all encoding
proteins that play a key role in lymphocyte-mediated
cytotoxicity.14-17 In addition, biallelic mutations in RAB27A
(OMIM *603868)18 give rise to a form of FHL known as Griscelli
syndrome type 2 (GS2). CTLs and NK cells from these patients
show defective degranulation and target cell killing; in addition,
these patients show partial oculocutaneous albinism with a
silver-gray sheen of hair and large pigment aggregates of
melanosomes within melanocytes in hair shafts. This combined
phenotype arises as a result of Rab27a’s ability to control both
melanosome secretion from melanocytes and cytolytic granule
secretion from CTLs.19-22 In melanocytes Rab27a mediates
secretion by binding to the synaptotagmin-like protein
melanophilin (Mlph), as well as the plus-end directed motor
protein myosin Va, which delivers melanosomes to cortical actin
for secretion.22-25 In CTLs Rab27a controls secretion of cytolytic
granules by binding the priming factor Munc13-4,15,26 and
mutations in either Munc13-4 or Rab27a prevent secretion of
granules once they have reached the immunologic synapse
formed between a CTL and a target cell. Interestingly, mutations
in Munc13-4 do not affect melanocyte function, and mutations in
Mlph do not give rise to FHL.27,28 In this way Rab27a controls
secretion in 2 different cell types by interacting with different
effector proteins.
Little is known about the precise sites of interaction between
Rab27a andMunc13-4. Earlier work mapped the Rab27a-binding
site on Munc13-4 to a motif spanning residues 280 to 285.29
However, this study did not pinpoint the key amino acids of
Rab27a that facilitate the interaction with Munc13-4 or whether
the same binding site mediates Rab27a interaction with Mlph.
Because Munc13-4 interacts with Rab27a in the guanosine
triphosphate (GTP)–bound state30 and the W73G mutation
disrupts binding to Munc13-4 and Mlph, this suggests that
changes around the GTP-binding site probably facilitate both
interactions.
In this article we examine the link between FHL and
pigmentation defects in 21 patients and identify novel mutations
in RAB27A, LYST, AP3B1, and, surprisingly, PRF1 in 1 patient.
We have also discovered a newly defined subpopulation of
patients with GS2 with mutations in RAB27A despite normal
pigmentation. We show that the RAB27A mutations in thesepatients disrupt interaction with Munc13-4 but do not affect
binding to Mlph. These mutations identify key amino acids
required for interaction with Munc13-4 and reveal discrete
binding sites for Munc13-4 and Mlph on Rab27a.METHODS
Patient cohort
In 1989, a registry for hemophagocytic lymphohistiocytosis (HLH) was
established,1 with the aim of centralizing patient information and
immunologic and genetic studies for diagnosis. HLH was defined by the
diagnostic criteria established by the Histiocyte Society.9
Of 901 patients referred between 1989 and 2013, 795 (88%) were given a
diagnosis of HLH. Of these, 592 underwent mutation analysis, which in 240
(40%) cases provided identification of a genetic diagnosis of FHL-related
condition. Within this cohort, we selected all cases in which pigment dilution,
identified by clinicians on the basis of hair color, was reported as part of the
clinical picture. In addition, we retrospectively reviewed all patients inwhom the
final diagnosis was FHL but in whom a genetic marker could not be attributed.
In such cases we decided to sequence the pigment dilution–related genes.
Informed consent was obtained in all cases by the parents or legal guardian. The
study was approved by the A.O.U. Meyer Institutional Review Board.Perforin expression and degranulation assays
PBMCs from patients with FHL and healthy donors were isolated by using
Ficoll gradient centrifugation. Perforin expression in NK cells (CD32CD561
cells of PBLs) was detected by means of intracellular staining (after fixation
and permeabilization) with the BD PharMingen (San Jose, Calif) reagent set
and cytofluorimetric analysis, as previously reported.31
Resting and activated NK cells were also tested by using the granule release
assay (GRA), quantifying cell-surface CD107a expression on coculture with
K562, as previously described.11,32,33 Briefly, anti-CD107a–phycoerythrin
mAb was added during the coculture for 3 hours at 378C in 5% CO2.
Thereafter, the cells were stained with anti-CD56–allophycocyanin and
anti-CD3–peridinin-chlorophyll-protein complexmAb and analyzed by using
flow cytometry (FACSCalibur, Becton Dickinson). All reagents were fromBD
Biosciences. Surface expression of CD107a was assessed in CD32CD561
cells (NK cells). Results were evaluated as DCD107a (ie, Percentage of
CD107a1 cells of stimulated 2 Percentage CD107a1 cells of unstimulated
sample) and defined as defectivewhen lower than the 10th percentile of values
in healthy control subjects.Cell culture
HEK 293 and P815 target cells were maintained in RPMI or Dulbecco
modified Eagle medium, respectively (Gibco, Life Technologies, Grand
Island, NY), supplemented with 10% FBS. Primary human CD81 T cells
were negatively selected from PHA blasts by using the Dynabeads Untouched
Human CD81 kit (Life Technologies), according to the manufacturer’s
instructions, and stimulated with irradiated (3000 rads) PBMCs and
1 mg/mL PHA (Oxoid, Hampshire, United Kingdom). Cells were grown in
RPMI supplemented with 5% human serum, 100 U/mL recombinant IL-2,
1 mmol/L sodium pyruvate, 2 mmol/L L-glutamine, 0.075% sodium
carbonate, and 50 mmol/L 2-mercaptoethanol to obtain CTLs. Polyclonal
NK cell populations were also obtained after NK cell purification (RosetteSep
Method; STEMCELL Technologies, Vancouver, British Columbia, Canada)
and cultured, as previously described.11Cytotoxicity assays
CTLs and P815 target cells were resuspended in RPMI (without phenol red,
Gibco), 2% FBS, and 0.5 mg/mL anti-CD3 antibody (clone UCHT1, BD
Biosciences); plated at different effector/target ratios as shown; and incubated
at 378C for 4 hours. The CytoTox 96 kit (Promega, Madison, Wis) was used to
assess target cell lysis per the manufacturer’s instructions. Activated purified
TABLE I. Main features of 21 patients with HLH and pigment dilution
Patient ID Sex/age Geographic origin GRA/cytotoxicity Mutation analysis Hair* Clinical outcome
UPN169 M/7 mo Italy NP/reduced RAB27A
c.514_518delCAAGC
p.Q172NfsX2;
13 y, cured after SCT
UPN241 F/2 mo Italy NP/reduced RAB27A c.550C>T
p.R184X second
mutation not identified
12.5 y, cured after SCT
UPN539 F/12 mo Italy Reduced/reduced RAB27A
c.148_149delAGinsC
p.R50Qfs
Died from disease
UPN731 F/11 mo Asian NP RAB27A c.662G>A
p.C221Y
2.8 y, alive, SCT ongoing
UPN775 M/2 mo Italy Reduced/NP RAB27A
c.514_518delCAAGC
p.Q172NfsX2*
Gray, small and large
ovoid granules
1.5 y, cured after SCT
UPN907 F/1 mo Asian NP RAB27A c.550C>T
p.R184X
Gray, large ovoid
granules
10 mo, cured after SCT
UPN440 F/24 mo Arab Reduced/reduced LYST c.1897A>T
p.K633X
8 y, cured after SCT
UPN698 F/16 mo Italy Reduced/NP LYST c.2304C>G
p.C768W Second
mutation not identified
Died from disease
UPN860 M/52 mo Czech Normal/NP LYST c.6122-4C>T
(splice error) Second
mutation not identified
5 y, cured after SCT
UPN886 M/26 mo Gipsy NP LYST c.8127del5ins12
p.L2709fs
Gray, medium granules,
spindle-shaped images
Died from disease at 3 y
UPN811 M/90 mo Australia NP AP3 c.2T>G p. M1R 8.5 y, alive, refused SCT
UPN351 M/4 mo United Kingdom/Afro NP/absent PRF1 c.50delT p.L17Rfs
c.658G>A p. G220S
11 y, cured after SCT
UPN42 M/6 mo Italy NP NP Died from disease at
10 mo
UPN43 M/3.1 y Italy NP NP Died from disease at 3.3 y
UPN379 M/not known Italy NP RAB27A WT Gray, small granules Lost to follow-up
UPN244 M/6 y Italy NP/absent RAB27A WT 18 y, cured after SCT
UPN264 F/3 mo Italy NP/normal RAB27A WT 10.5 y, cured after SCT
UPN299 M/2.5 y Italy Normal/normal RAB27A, LYST, AP3: WT Gray, medium granules 12.5 y, alive, recurrent
infections
UPN540 F/12 y Italy Reduced/normal RAB27A, LYST, AP3: WT Died from disease at
12.2 y
UPN645 M/15.5 y United Kingdom Normal/NP RAB27A, LYST, AP3: WT 17.7 y, alive with
lymphocytopenia and
thrombocytopenia
UPN797 M/21 mo Italy Normal/NP RAB27A, LYST, AP3: WT Gray, medium granules,
spindle-shaped images
Died from disease at 2 y
Novel mutations are shown in boldface.
NP, Not performed; SCT, stem cell transplantation; UPN, Unique patient number (UPN 42 and 43 are siblings); WT, wild-type.
*Hair study: small granules 5 about 0.5-1.5 3 0.3-0.8 mm; medium granules 5 about 2-5 3 1 mm; large granules 5 about 10 3 3-6 mm; spindle-shaped black images 5 up to
about 10 3 1-2 mm and were interpreted as air-containing fissures within the hair cortex rather than pigment.
Homozygous.
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line in a standard 51Cr-release assay.11Biochemical studies
HEK 293 cells were lipofected (Lipofectamine 2000, Life Technologies)
with full-length human Rab27a–green fluorescent protein (GFP) locked in its
GTP-bound form by mutation Q78L with and without additional mutations
A76V, Y159C, S163R, or p.R141_V142delinsI and either Munc13-4–GFP or
Mlph-GFP.
Lipofected HEK 293 cells were lysed with PBS plus 1% Triton X-100,
4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), 1 mmol/L
CaCl2, and 1mmol/LMgCl2. Lysates were preclearedwith 100mLof ProteinGBead slurry (GEHealthcare, Fairfield, Conn)with rotating at 48C for 30minutes
and then split into 3 samples: no antibody, rabbit anti-Rab27a (produced in rab-
bits immunized with human Rab27a-GST and screened against lysates from
healthy donor and Rab27A-deficient human and mouse cell lines), and either
goat anti–Munc13-4 (Everest Biotechnology, Upper Heyford, United
Kingdom) or rabbit anti-Mlph (Abcam, Cambridge, United Kingdom). Lysates
and antibodieswere incubated for 2hourswith rotatingat 48C, followedbyaddi-
tion of Protein G beads and incubation for 1 hour. Beads were washed 4 times
with lysis buffer, resuspended with sample buffer, and boiled at 958C for 5 mi-
nutes, and the eluate was then transferred to a fresh tube.
Samples were separated on a 10% acrylamide gel and transferred onto
nitrocellulose. Membranes were blocked in PBS with 0.2% Tween 20 and 5%
dried skim milk powder and incubated with primary antibodies (as used in IP
TABLE II. Main features of 6 patients from 3 families with HLH but no pigment dilution in whom GS2 was diagnosed based on
RAB27A mutations
Patient ID Sex/age GRA/cytotoxicity Mutation Hair* Clinical outcome
UPN154 M/6.8 mo NP c.422_424delGAG p.R141_V142delinsI Died from disease
UPN155 M/0.5 mo NP/absent c.422_424delGAG p.R141_V142delinsI Reactivated after MRD SCT; died from
disease
UPN313 F/10.7 y Reduced/reduced c.422_424delGAG p.R141_V142delinsI Mild blond; small- and
medium-sized granules
Reactivated; 16 y, cured after UD SCT
UPN324 F/4 y Absent/absent
(Fig 1)
c.422_424delGAG p.R141_V142delinsI
c.487A>C p.S163R
Reactivated, 13 y, cured after UD SCT
UPN396 M/7.3 y Absent/absent
(Fig 1)
c.227C>T p. A76V c.476A>G p. Y159C Mild blond; small-sized
granules
Reactivated; 14 y, cured after UD SCT
UPN226 M/5 y Reduced/reduced c.514_518delCAAGC p.Q172Nfs
c.422_424delGAG p.R141_V142delinsI
17 y, cured after SCT
Patients UPN154, UPN155, and UPN313 are siblings. Novel mutations are shown in boldface.
MRD, Matched related donor; NP, not performed; SCT, stem cell transplantation; UD, unrelated donor.
*Hair study: small granules 5 about 0.5-1.5 3 0.3-0.8 mm; medium granules 5 about 2-5 3 1 mm; large granules 5 about 10 3 3-6 mm; spindle-shaped black images 5 up to
about 10 3 1-2 mm and were interpreted as air-containing fissures within the hair cortex rather than pigment.
Homozygous.
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[Proteintech, Chicago, Ill]). Membranes were washed 3 times for 10 minutes
with PBS plus 0.2% Tween 20 and incubated in secondary antibodies
conjugated to horseradish peroxidase (HRP; anti-goat HRP, anti-mouse HRP,
and anti-rabbit light chain–specific HRP; all from Jackson ImmunoResearch,
West Grove, Pa), washed again as before with an additional 10-minute wash
with PBS alone, and then developed with UptiLight (Cheshire Sciences,
Chester, United Kingdom) and exposed on x-ray film (Kodak, Rochester, NY).
Pigmentation analysis
Hair samples were cleared in xylene, mounted with synthetic resin (Eukitt;
Fluka, Sigma-Aldrich, St Louis, Mo), and observed under a Leitz (Wetzlar,
Germany) light microscope equipped with a ProgRes C10plus camera and
dedicated software (Jenoptik, Jena, Germany).Mutation analysis
Genomic DNA was isolated from peripheral blood samples by using the
BioRobot EZ1Workstation (Qiagen, Hilden, Germany). RAB27A, LYST,
AP3B1, and PRF1 genes were analyzed by means of direct sequencing. The
coding exons and exon-intron boundaries were amplified and directly
sequenced in both directions with the BigDye Terminator Cycle Sequencing
Ready Reaction Kit (Applied Biosystems, Foster City, Calif). Sequences
obtained with an ABI Prism 3130XL Sequence Detection System (Applied
Biosystems) were analyzed and compared with the reported gene structure
by using the dedicated software SeqScape (Applied Biosystems). All
mutations were confirmed in the parents.In silico analysis
All variants of the sequencewere searched in dbSNP (http://www.ncbi.nlm.
nih.gov/snp/). For variants not reported, we used 3 bioinformatics tools to
predict whether an amino acid substitution could be benign or deleterious:
SIFT (Sorting Intolerant From Tolerant; http://sift.jcvi.org/), PolyPhen
(Polymorphism Phenotyping; http://genetics.bwh.harvard.edu/pph/), and
Pmut (http://mmb.pcb.ub.es/Pmut).34RESULTS
Patients with FHL with partial albinism with
assigned genetic markers
A total of 21 children from 20 families were reported to have
HLH and some degree of pigment dilution. They accounted for
2.5% of the total cases of HLH enrolled in the registry. In 12
patients a genetic defect associated with pigment dilution andimmunodeficiency could be identified (Table I) and assigned as
follows: GS2, 6 cases; Chediak-Higashi syndrome, 4 cases; and
Hermansky-Pudlak syndrome type 2, 1 case. Unexpectedly, we
found biallelic PRF1 mutations in 1 patient with albinism. The
association between albinism and FHL type 2 was never reported
and appears to be noncausal.35
We identified 7 novel mutations in the RAB27A, LYST, and
AP3B1 genes. Among these, 3 were missense mutations, and all
were predicted by bioinformatics facilities as damaging protein
function. In 2 cases we observed a single variation: patient
UPN241 has a stop mutation in RAB27A, with protein study
showing a protein defect, and patient UPN860 has a single
mutation in LYST, an intronic defect that is predicted by the
software Human Splicing Finder to create a new acceptor site.
Full characterization of these patients has yet to be completed.
Patients with FHL with partial albinism with
unassigned genetic markers
For 9 patients, a genetic marker in one of the pigment dilution–
associated genes (or one of the FHL-related genes) could not be
assigned (Table I). In 2 siblings (patients UPN42 and UPN43) the
genetic study (as well as the functional studies) could not be
performed because of lack of consent. Two patients had findings
suggestive of an underlying genetic defect (ie, defective
degranulation at GRA [patient UPN540] or defective cellular
cytotoxicity [patient UPN244]). Another patient with no assigned
marker (patient UPN299) had HLH at 2.5 years of age (with
normal GRA and cytotoxicity but abnormal T-cell proliferation
after CD3 stimulation), which resolved after initial treatment.
This patient was later given a diagnosis of a familial depigmenta-
tion syndrome combined with recurrent infections. The family of
patient UPN299 is currently under investigation for identification
of a possible novel defect. The remaining 4 patients had either
normal degranulation (n 5 2) or normal cytotoxicity (n 5 1) or
were not investigated. The unassigned patients will be subject
to exome sequencing in the near future.
Analysis of pigmentation dilution in patients with
FHL with partial albinism
Microscopic analysis of hair for pigment dilution produced
varied results among subjects (Table I). All pigment granules
FIG 1. CTLs from patients UPN396 and UPN324 show severely reduced
ability to kill target cells. A, Percentage killing of P815 target cells by means
of redirected lysis with anti-CD3 mediated by CTLs from a healthy donor
(HD; triangles), patient UPN324 (squares), and patient UPN396 (circles) after
4 hours. Each data point was run in triplicates. The image is representative
of 3 independent experiments. B, Immunoblots of Rab27a and Munc13-4 in
CTLs from a healthy donor (HD) and patients UPN324 and UPN396. Proteins
from lysates were separated by means of SDS-PAGE, transferred onto
nitrocellulose, and probed with protein-specific antibodies against
Rab27a, Munc13-4, and actin. Images are representative of 3 independent
experiments.
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In patient UPN396 there were fine pigment granules (up to
about 1.5 3 0.8 mm in diameter), as in normal blond hair. In
patient UPN313 there were fine pigment granules accompanied
by some medium-sized granules (about 5 3 3 mm in diameter).
In 2 patients (patients UPN775 and UPN907) there were large
granules (about 10 3 3 to 10 3 6 mm in diameter) unevenly
distributed along the hair. One of these patients (patient
UPN775) also had some hairs with fine pigment granules and
no large granules.
In 3 subjects (patients UPN299, UPN797, and UPN886) there
were medium-sized pigment granules. In 2 of these subjects
(patients UPN797 and UPN886), therewere also occasional black
spindle-shaped (up to about 103 1 or 2 mm) images close to the
hair axis but not exactly axial. Given the shape and intensely black
color, these images were interpreted as air-containing fissures
within the hair cortex. We have not been able to define the
correlation between the degree of hair depigmentation and
specific RAB27A mutations.Patients with GS2 but no evidence of pigment
dilution
In addition to the patients with FHL and partial albinism
(defined on the basis of the partial or complete absence of normal
hair color), 45 additional patients with suspected FHL (caused by
either familial disease or a confirmed severe functional defect in
degranulation or cytotoxicity assays) and apparently normal
pigmentation were identified, in whom we did not find biallelic
mutations in the FHL-related genes PRF1, UNC13D, STX11, and
STXBP2 (or SH2D1A for XLP1 and XIAP for XLP2 in male sub-
jects). Thus we asked whether they might have mutations in
RAB27A that could give rise to immune defects underlying
HLH in the absence of pigment dilution by preserving binding
to Mlph. Of them, 29 could be investigated by using mutation
analysis. Analysis of the RAB27A gene in 6 patients from 4 unre-
lated families of southern European origin unexpectedly showed
biallelic mutations inRAB27A (Table II). All of these patients car-
ried at least 1 novel mutation. Remarkably, the p.R141_V142de-
linsI mutation was shared by 5 patients from 3 unrelated families
with GS2 but normal hair pigmentation: 3 homozygous siblings
(patients UPN154, UPN155, and UPN313), 1 patient in associa-
tion with the novel missense mutation p.S163R (patient
UPN324), and another patient (patient UPN226) in association
with the known p.Q172Nfs mutation. Patient UPN396 carried 2
novel missense mutations (A76Vand Y159C). All missense mu-
tations were tested by using bioinformatics software (PolyPhen-
2) and defined to be pathogenic. It is interesting to note that within
the same family, 2 patients (patients UPN154 and 155) had a quite
typical early onset of GS2, whereas the third case (patient
UPN313) had the disease only after the age of 10 years. When re-
viewing the hair phenotype of these patients, we confirmed that
none had silver-gray hair, and only 2 were reported to have
some ‘‘light or blond hair.’’
The results of analysis in patients UPN396 and UPN324 are
shown in Fig 1, A, and Fig E1, which is available in this article’s
Online Repository at www.jacionline.org. Both exhibited a
severely reduced ability to kill target cells (maximal 20%
cytotoxicity) compared with a healthy donor (maximal 80%
cytotoxicity). To determine whether these patients still expressed
Rab27a protein, we analyzed lysates from patients’ CTLs using
immunoblotting. We noted that the mutations found both in
patient UPN396 (A76V and Y159C) and patient UPN324
(S163R and p.R141_V142delinsI) all resulted in reduced
Rab27a protein levels in lysates from patients’ CTLs (Fig 1, B).
Interestingly, the Munc13-4 protein level was unaffected
(Fig 1, B).Mutations on one face of Rab27a can disrupt
binding to Munc13-4 but not Mlph
The identification of missense mutations in Rab27a that
affected only CTL effector function but not melanocytes offered
a unique opportunity to compare the molecular function of
Rab27a in cytotoxicity versus pigmentation. Because the
interaction of Rab27a with Munc13-4 is required for granule
secretion from CTLs and the interaction between Rab27a and
Mlph is required for melanosome secretion, we hypothesized that
this might be caused by mutations in Rab27a that selectively
disrupted binding with Munc13-4 but not Mlph. To investigate
this hypothesis, we used the structure of mouse Rab27a in
complex with human synaptotagmin-like protein 2a (Slp2a) to
FIG 2. Location of amino acid mutations in patients UPN394 and UPN326. Cartoon representation of mouse
Rab27a (yellow) in complex with human Slp2a (cyan; 3BC114) viewed from the front (left) and turned around
the y axis to the left by 908 (middle). The bound GTP analog (GppNHp) is shown as an orange stick model
and the magnesium ion as a green sphere, and helix 6 is highlighted in purple. Insets magnify the regions
where mutations in patients UPN396 and UPN324 occurred, with Y159C (top right), A76V (bottom left),
S163R (bottom middle), and p.R141_V142delinsI (bottom right) shown.
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p.R141_V142delinsI might affect potential interaction sites or
the stability of the protein.36 The mutation A76V lies adjacent to
the active site of Rab27a, where the Mg21 ion binds (green
sphere, Fig 2) and GTP hydrolysis occurs, suggesting that the
catalytic site might be impaired by this mutation. This is
consistent with previous findings that A76V is a deleterious
mutation found in patients with GS2 with immunodeficiency
and albinism.37,38 Interestingly, residues Y159, S163, and R141
all lie close to each other in the 3-dimensional structure on an
outer face of Rab27a, and the structure provides insights into
why mutations of these residues might disrupt a possible
interaction with Munc13-4. The structure shows that Y159 forms
a hydrogen bond to the carboxy oxygen of glutamate 161. When
mutated to a cysteine, this bond would be lost, and the
conformation of the protein would be altered. Similarly, S163
can form a hydrogen bond to the carboxy oxygen of aspartate
136, and this would be abolished by mutation to arginine
(Fig 2, second inset in second row). The deletion of 3 bases in
the RAB27A gene (c.422_424delGAG) is found in 5 of the 6 novel
patients with GS2 and results in deletion of R141 and replacement
of V142 by isoleucine. Interestingly, residue R141 can also form
hydrogen bonds with the carboxy group of glutamate 161 (Fig 2,
third inset in second row), and these bonds would no longer exist
when this residue is deleted.
Although active (GTP-bound) Rab27a in CTLs and NK cells
binds to the priming factor Munc13-4, in melanocytes the key
effector protein of Rab27a is the synaptotagmin-like protein
Mlph. Therefore we investigated the effect of these mutations onthe ability of active Rab27a to bind to either Munc13-4 orMlph to
determine whether these mutations might disrupt the binding of
Munc13-4 but not Mlph and explain the loss of cytotoxicity
without the loss of pigmentation. We coexpressed a point mutant
of Rab27a (Q78L) that lacks GTP hydrolysis activity36,39,40 and
each of the 4 mutations (A76V, Y159C, S163R, and delR141)
found in patients (Table I), together with Mlph or Munc13-4 in
HEK 293 cells, and examined whether the Rab27a mutations
identified affected binding to Munc13-4 and Mlph.
When Munc13-4 immunoprecipitates were probed with
anti-Rab27a antibodies, neither the S163R (Fig 3, A, lane 4) nor
the p.R141_V142delinsI (Fig 3, A, lane 6) mutant forms of
Rab27a were able to coprecipitate with Munc13-4 as effectively
as native Rab27a (Fig 3, A, lane 2). Immunoprecipitation with
Mlph showed that Rab27a S163R also showed greatly reduced
binding to Mlph (Fig 3, B, lane 4). However, Rab27a
p.R141_V142delinsI was able to bind Mlph (Fig 3, B, lane 6).
Therefore the combination of these alleles would result in a
specific loss of Rab27a interaction with Munc13-4 but not
Mlph. These results provide a possible molecular explanation
for the atypical GS2 phenotype seen in patients with severe
immunodeficiency but lack of a pigmentation defect in patients
UPN154, UPN155, and UPN313, who were all homozygous for
the mutation at R141, as well as patient UPN324, in whom the
R141 mutation is found on one allele and the S163R mutation
is found on the other allele. The selective loss of Munc13-4 but
not Mlph binding of the p.R141_V142delinsI mutation also
provides a molecular explanation for patient UPN226 because
p.Q172Nfs predicts production of a truncated protein after
FIG 3. Effect of mutations in Rab27a on binding to Mlph and Munc13-4.
Immunoblots showing coimmunoprecipitations are shown. A, Munc13-4
with Rab27a (lanes 1 and 2), Rab27a-S163R (lanes 3 and 4), and Rab27a-
R141lfs (lanes 5 and 6). Images are representative of 3 independent
=
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were available, this could not be tested.
The mutations in patient UPN396 differed, with A76V lying in
the catalytic site of Rab27a and Y159C lying close to S163, which
was mutated in patient UPN324. Analyzing the ability of A76V
and Y159C to interact with Munc13-4 and Mlph, we found that
neither A76V nor Y159C could coprecipitate Munc13-4 as
effectively as active Rab27a (Fig 3, C), although both could
coprecipitate Mlph as effectively as active Rab27a (Fig 3, D).
These findings explain why there is a loss of cytotoxicity in
UPN396 (Fig 1, A) without a loss of pigmentation.DISCUSSION
In this study we asked whether patients with FHL with
immunodeficiency but with normal pigmentation might
sometimes have mutations that affected cellular cytotoxicity
without affecting pigmentation. We specifically focused on
mutation analysis of RAB27A, LYST, and AP3B1 in patients
with FHL with pigment dilution, as well as a cohort with no
clinical evidence of pigment dilution but nomutations in the other
known FHL-related genes.
The unexpected finding that 6 patients with HLH but no
albinism (only ‘‘light or blond’’ hair in 2 patients) showed biallelic
mutations in RAB27A supports the concept that RAB27A
mutations should be investigated in patients with suspected
FHL, even if no pigmentation defect has been reported. Notably,
in all these families we found a severe immune defect, affecting
degranulation and cytotoxicity.
We identified 4 mutations at A76, R141, Y159, and S163 that
specifically disrupt the interaction of Rab27a with Munc13-4 but
not Mlph. The mutations R141, Y159, and S163 are all close to
each other in the 3-dimensional structure of Rab27a (Fig 2), and
these results indicate that this face of Rab27a forms an important
part of the binding site for Munc13-4. Two separate mutations
reported here affect intramolecular bonds to residue 161 in
Rab27a: R141 precedes helix a4 (purple), whereas residue
Y159 lies just after. Therefore it is possible that both R141 and
Y159, by binding to E161, affect the position of helix a4
and thus might create an interface for the interaction with
Munc13-4. Interestingly, this interface is on the opposite side of
Rab27a from its Slp2a-binding site, suggesting that Rab27a can
bind both Slp2a and Munc13-4 simultaneously.36 The mutation
A76V lies near the active site of Rab27a, where GTP hydrolysis
occurs. The fact that this mutation disrupts Munc13-4 binding but
not Mlph binding suggests that a conformational change that
occurs in this area can affect Munc13-4 but not Mlph binding.
Other nearby mutations (W73G) have been found to affect the
GTPase activity of Rab27a while retaining Mlph binding.19
Although previous investigations highlighted the linear motif of
Munc13-4 required for the interaction with Rab27a,41 the
Munc13-4–binding site on Rab27a had not been defined. By
examining RAB27A mutations that give rise to FHL with normal
pigmentation, we have pinpointed a region of Rab27a that is
required for interaction with Munc13-4.experiments. B, Rab27a (lanes 1 and 2), Rab27a-S163R (lanes 3 and 4),
and Rab27a-R141lfs (lanes 5 and 6) with Mlph. Membranes were probed
with specific antibodies against Rab27a (top) or Mlph (bottom). C and D,
As above but with Rab27A A76V and Y159C. Proteins were immunoprecip-
itated with anti-Munc13-4 or Mlph and probed for Rab27a, Munc13-4, and
Mlph.
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screening patients with HLH for Rab27a defects, even when
pigmentation is normal, but also provide the structural basis for
these distinct phenotypes by mapping the binding sites between
Rab27a and Munc13-4.
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Clinical implications: Our study highlights the need for
RAB27A sequencing in patients with FHL without albinism,
in whom a diagnosis of GS2 can be easily missed.REFERENCES
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FIG E1. Cytolytic activity of polyclonal activated NK cells from the 3
representative patients, patient UPN440 with Chediak-Higashi syndrome,
patient UPN539 with GS2 with pigment dilution, and patient UPN396 with
GS2 without pigment dilution, in comparison with healthy control subjects
(means 6 SEMs) against the 221 B-EBV target cell line.
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